| Literature DB >> 22114741 |
Huan Zheng1, Ming Luo, Yi Shen, Hong Fang.
Abstract
Objective. To study the effects of 6 months' exercise training on ventricular function in hypertensive patients. Methods. Both groups received routine anti-hypertensive pharmacological therapy and one received a 6 months' exercise program in addition. All patients underwent incremental cardiopulmonary exercise test and echocardiography in baseline and after 6 months. Results. (1) In 6 months' follow-up, Peak(VO2), Power(max) (max workload), AT (anaerobic threshold), VO(2AT) (VO(2) at anaerobic threshold), t(AT) (time from beginning to anaerobic threshold) (P < .05), were increased in the exercise group. HR(rest) (Heart rate at rest) was decreased (P < .05). LAVI (left atrial volume index), peak mitral filling velocities during early (E) and late (A) diastole E/A ratio, DT(deceleration time of the mitral E wave), IVST(Interventricular septum thickness in diastole), tissue Doppler indice Mean Ea/Aa ratio (P < .05) were also improved. (2) Correlation analysis: 4 variates had significant effect on change of Peak(VO2) in the exercise group: age (r = -0.39), change of HR(rest) (r = 0.59), change of E/A (r = 0.55), change of Mean Ea/Aa (r = 0.58); Through analyzing 2 groups patients' baseline values, their age (β = - 0.32), VO(2AT) (β = 0.29), HR(rest) (β = - 0.25), LAVI (β = - 0.24), E/A (β = 0.41) were found to be independent predictors of MeanEa/Aa. P-value under .05 was considered statistically significant. Conclusion. 6 months' exercise could enhance hypertensive patients' aerobic exercise level and diastolic function to a certain extent.Entities:
Year: 2011 PMID: 22114741 PMCID: PMC3196261 DOI: 10.1155/2011/497690
Source DB: PubMed Journal: Rehabil Res Pract ISSN: 2090-2867
Baseline clinical, morphological, and echographic characteristics of trained patients and untrained controls.
| Exercise group | Control group |
| |
|---|---|---|---|
|
|
| ||
| Age (years) | 64.6 (3.7) | 65.0 (3.1) | .641 |
| Male/female | 16/9 | 15/10 | .329 |
| BMI (kg/m2) | 24.7 (3.6) | 23.8 (3.0) | .436 |
| Hypertension duration (years) | 13.2 (3.5) | 12.9 (3.8) | .712 |
| HRrest (beats/min) | 74.5 (6.1) | 72.6 (7.4) | .193 |
| SBPrest (mmHg) | 138 (14) | 140 (13) | .384 |
| DBPrest (mmHg) | 78 (13) | 76 (15) | .211 |
| LAVI (ml/m2) | 35.4 (2.1) | 36.0 (1.8) | .431 |
| LVDd (mm) | 47.4 (5.5) | 48.1 (3.3) | .828 |
| LVSd (mm | 32.4 (2.6) | 32.8 (2.4) | .783 |
| IVST (mm) | 10.8 (0.9) | 11.1 (0.7) | .672 |
| PVST (mm) | 10.3 (0.4) | 10.4 (0.3) | .532 |
| LVEF (%) | 54.5 (5.5) | 55.0 (4.9) | .471 |
BMI: body mass index; HRrest: heart rate at rest; SBPrest: systolic blood pressure at rest; DBPrest: diastolic blood pressure at rest; LAVI: left atrial volume index; LVDd: left ventricular end-diastolic diameter; LVSd: left ventricular end-systolic diameter; IVST: interventricular septum thickness in diastole; PVST: posterior ventricular septum thickness in diastole; LVEF: left ventricular ejection fraction.
Pharmacological therapy at baseline and after 6 months in the 2 patient groups.
| Exercise group | Control group | Differences in changes between groups | |||
|---|---|---|---|---|---|
|
|
| ||||
| Baseline | 6 months | Baseline | 6 months |
| |
| Fosinopril | 12.2 (3.8) | 11.8 (3.9) | 11.9 (4.1) | 12.5 (5.0) | .732 |
| (mg/d) [ | [17] | [17] | [16] | [16] | |
| Benazepril | 8.3 (2.3) | 7.8 (2.2) | 8.4 (2.4) | 9.0 (2.3) | .819 |
| (mg/d) [ | [6] | [6] | [7] | [7] | |
| Bisoprolol | 3.8 (1.5) | 3.4 (1.6) | 4.0 (1.3) | 4.3 (1.5) | .328 |
| (mg/d) [ | [14] | [14] | [5] | [5] | |
| Nitrendipine | 13.6 (4.3) | 14.1 (4.1) | 14.0 (3.9) | 13.5 (4.2) | .136 |
| (mg/d) [ | [10] | [10] | [10] | [10] | |
| Felodipine | 6.9 (2.4) | 6.9 (2.4) | 7.1 (2.2) | 7.1 (2.2) | 1 |
| (mg/d) [ | [9] | [9] | [9] | [9] | |
| Hydrochlorothiazide | 42.6 (9.5) | 41.9 (8.8) | 42.5 (9.4) | 42.5 (9.4) | .739 |
| (mg/d) [ | [7] | [7] | [7] | [7] | |
| Aspirin | 100 | 100 | 100 | 100 | 1 |
| (mg/d) [ | [25] | [25] | [25] | [25] | |
Values in parenthesis refer to total daily dosage; (n) refers to the number of patients consuming the drug.
Cardiopulmonary exercise test parameters and clinical characteristics at baseline and after 6 months in the 2 patient groups.
| Exercise group | Control group |
| |||
|---|---|---|---|---|---|
|
|
| ||||
| Baseline | 6 months | Baseline | 6 months | ||
| PeakVO2 (ml × kg−1× min−1) | 14.1 (1.5) | 16.5 (2.1) | 13.9 (1.6) | 13.6 (2.2) | .008 |
| PeakVO2% | 50.3 (2.1) | 60.4 (2.6) | 47.6 (3.8) | 46.8 (4.2) | .013 |
| Powermax (W) | 67.4 (8.2) | 76.9 (6.3) | 66.8 (7.8) | 67.3 (8.2) | .029 |
| AT (W) | 61.3 (6.9) | 71.0 (7.7) | 60.8 (7.4) | 60.6 (8.1) | .017 |
| VO2AT (ml × kg−1× min−1) | 11.2 (2.9) | 13.2 (2.7) | 11.4 (3.1) | 10.9 (2.8) | .003 |
| tAT (s) | 6.7 (0.8) | 8.2 (1.0) | 7.0 (0.7) | 6.9 (0.9) | .011 |
| SBPrest (mmHg) | 138 (14) | 136 (15) | 140 (13) | 138 (14) | .271 |
| DBPrest (mmHg) | 78 (13) | 80 (15) | 76 (15) | 75 (16) | .295 |
| HRrest | 74.5 (6.1) | 71.6 (5.5) | 72.6 (7.1) | 72.9 (6.4) | .024 |
| BMI (Kg/m2) | 24.7 (3.6) | 23.8 (4.0) | 23.8 (3.0) | 23.7 (3.1) | .442 |
PeakVO2: peak oxygen cousumption; PeakVO2%: the percentage of actual PeakVO2 in the predicted value; Powermax : maximal workload; AT: ventilatory anaerobic threshold; VO2AT: oxygen consumption at anaerobic threshold; tAT: time from beginning to anaerobic threshold; SBPrest: systolic blood pressure at rest; DBPrest: diastolic blood pressure at rest; HRrest: heart rate at rest; BMI: body mass index.
Doppler echocardiographic parameters at baseline and after 6 months in the 2 patient groups.
| Exercise group | Control group |
| |||
|---|---|---|---|---|---|
|
|
| ||||
| Baseline | 6 months | Baseline | 6 months | ||
| LAVI (ml/m2) | 35.1 (4.2) | 32.3 (3.8) | 35.7 (3.9) | 35.9 (4.2) | .017 |
| LVDd (mm) | 47.4 (5.5) | 46.9 (6.1) | 48.1 (3.3) | 48.3 (4.0) | .592 |
| LVSd (mm) | 32.4 (2.6) | 33.1 (2.8) | 32.8 (2.4) | 33.1 (3.1) | .273 |
| IVST (mm) | 10.8 (0.9) | 10.5 (1.0) | 11.1 (0.7) | 10.9 (0.9) | .269 |
| PVST (mm) | 10.3 (0.4) | 10.2 (0.5) | 10.4 (0.3) | 10.4 (0.6) | .727 |
| LVEF (%) | 54.5 (5.5) | 55.1 (6.2) | 55.0 (4.9) | 54.8 (4.6) | .614 |
| E/A | 0.75 (0.07) | 0.88 (0.06) | 0.72 (0.05) | 0.70 (0.07) | .004 |
| DT (ms) | 220 (14) | 242 (18) | 226 (20) | 218 (19) | .018 |
| IVRT (ms) | 109 (12) | 89 (11) | 106 (14) | 109 (13) | .037 |
| S/D | 1.4 (0.2) | 1.1 (0.3) | 1.5 (0.2) | 1.2 (0.2) | .008 |
| Ea/Aa [1] | 0.87 (0.26) | 1.12 (0.28) | 0.90 (0.24) | 0.96 (0.30) | .019 |
| Ea/Aa [2] | 0.92 (0.18) | 1.20 (0.24) | 0.89 (0.17) | 0.87 (0.25) | .006 |
| Ea/Aa [3] | 0.85 (0.17) | 1.05 (0.23) | 0.86 (0.23) | 0.86 (0.19) | .028 |
| Ea/Aa [4] | 0.96 (0.16) | 1.21 (0.18) | 0.96 (0.27) | 0.93 (0.29) | .036 |
| Mean Ea/Aa | 0.89 (0.23) | 1.19 (0.21) | 0.91 (0.23) | 0.90 (0.24) | .011 |
LAVI: left atrial volume index; LVDd: left ventricular end-diastolic diameter; LVSd: left ventricular end-systolic diameter; IVST: interventricular septum thickness in diastole; PVST: posterior ventricular septum thickness in diastole; LVEF: left ventricular ejection fraction; E: early diastolic mitral inflow peak velocity; A: late diastolic mitral inflow peak velocity; DT: deceleration time of the mitral E wave; IVRT: isovolumic relaxation time; S/D: systolic velocity to diastolic velocity ratio by pulmonary veins; Ea: early diastolic myocardial peak velocity; Aa: late diastolic myocardial peak velocity; Ea/Aa [1], Ea/Aa [2], Ea/Aa [3], and Ea/Aa [4] refer to Ea/Aa ratio at septum mitral annulus, lateral mitral annulus, interventricular medium septum, and lateral medium wall, respectively; meanEa/Aa = (Ea/Aa [1] + Ea/Aa [2] + Ea/Aa [3] + Ea/Aa [4])/4.
Univariate correlation in exercise group.
| Δ PeakVO2 | |
|---|---|
| Age | −0.39* |
| Hypertension-duration | −0.46 |
| Δ BMI | 0.14 |
| Δ SBPrest | 0.22 |
| Δ DBPrest | 0.31 |
| Δ HR | 0.59* |
| Δ LAVI | 0.20 |
| Δ LVDd | 0.28 |
| Δ LVSd | 0.49 |
| Δ IVST | 0.17 |
| Δ PVST | 0.27 |
| Δ LVEF | 0.34 |
| Δ E/A | 0.55* |
| Δ DT | 0.41 |
| Δ IVRT | 0.34 |
| Δ MeanEa/Aa | 0.58* |
*P < .05, Δ means change of those values after 6 months.
Multi-variate regression analysis for Mean Ea/Aa.
|
| |
|---|---|
| Age | −0.32* |
| VO2AT | 0.29* |
| HRrest | −0.25* |
| LAVI | −0.24* |
| E/A | 0.41* |
*P < .05.